U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Edwards SJ, Barton S, Thurgar E, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jan. (Health Technology Assessment, No. 19.7.)

Cover of Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.

Show details

Chapter 5Assessment of factors relevant to the NHS and other parties

End-of-life criteria

Tables 153–155 assess the treatments against the NICE end-of-life criteria,145 by network. The TAG considers that it is likely that the criteria for end of life have not been met by any treatment. For the platinum-sensitive networks (PS network 1 and PS network 2) life expectancy for the baseline treatments are estimated by the TAG to be > 24 months. For the platinum-resistant population, no evaluable treatment offers a survival gain of greater than three months.

TABLE 153

TABLE 153

Assessment of treatments in PS network 1 against NICE end-of-life criteria

TABLE 155

TABLE 155

Assessment of treatments in the PRR network against NICE end-of-life criteria

TABLE 154

TABLE 154

Assessment of treatments in PS network 2 against NICE end-of-life criteria

Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Edwards et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK269563
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (8.4M)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...